Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.
Maxion Therapeutics has raised €83M across 3 funding rounds from 8 investors, most recently a Series A round in Mar 2025. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2025-03-17 | Series A | €66M | BGF,British Patient Capital,Eli lilly and company,General Catalyst,LifeArc Ventures,Monograph Capital+1 more | View deal → |
| 2023-04-19 | Grant | €2.3M | Innovate UK | View deal → |
| 2023-02-16 | Series A | €15M | BGF,LifeArc Ventures,Monograph Capital | View deal → |
